Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 1.425 EUR -2.06%
Market Cap: €976.3m
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

Assets
+
3Y
+24%
5Y
+48%
10Y
+662%
Liabilities
+
3Y
+15%
5Y
+14%
10Y
+471%
Equity
+
3Y
+32%
5Y
+94%
10Y
+934%

Balance Sheet Decomposition
Pharming Group NV

Balance Sheet
Pharming Group NV

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2001 Dec-2002 Dec-2003 Dec-2004 Dec-2005 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
1
1
3
22
15
26
51
20
16
10
4
5
17
34
32
32
62
85
74
205
192
207
62
55
Cash Equivalents
1
1
3
22
15
26
51
20
16
10
4
5
17
34
32
32
62
85
74
205
192
207
62
55
Short-Term Investments
0
0
0
4
6
5
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
152
113
Total Receivables
0
1
0
0
1
2
1
1
1
10
1
0
1
1
3
11
11
17
29
32
28
25
43
50
Accounts Receivables
0
1
0
0
0
0
0
0
0
9
0
0
0
1
2
6
9
16
29
24
18
21
35
42
Other Receivables
0
0
0
0
0
0
0
0
0
1
0
0
0
1
1
5
1
1
0
8
10
4
7
9
Inventory
0
3
3
3
4
9
12
11
11
9
7
2
5
13
16
18
19
18
16
21
27
42
57
56
Other Current Assets
9
4
1
1
1
1
11
1
1
0
2
1
2
0
0
1
1
2
0
5
3
3
4
5
Total Current Assets
10
8
6
29
26
42
79
36
29
29
13
8
25
49
51
62
94
122
119
263
249
278
316
278
PP&E Net
8
6
4
5
6
8
8
6
7
8
11
7
6
6
6
6
9
9
16
22
33
39
33
24
PP&E Gross
8
6
4
5
6
8
8
6
7
8
11
7
6
6
6
6
9
9
16
22
33
39
33
24
Accumulated Depreciation
4
4
4
2
2
3
3
1
5
5
6
5
4
5
6
7
8
11
14
19
23
20
27
30
Intangible Assets
5
2
2
4
4
20
19
20
19
20
3
1
0
1
1
56
60
56
79
94
84
75
71
61
Goodwill
1
0
0
0
0
9
9
7
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Long-Term Investments
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
7
9
10
10
4
Other Long-Term Assets
0
0
0
1
1
1
1
1
3
20
2
1
0
0
0
2
14
41
35
32
22
24
31
32
Other Assets
1
0
0
0
0
9
9
7
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Assets
24
N/A
17
-32%
13
-23%
38
+198%
35
-8%
79
+129%
114
+45%
67
-41%
56
-17%
37
-33%
25
-34%
17
-32%
31
+87%
56
+77%
58
+4%
126
+119%
176
+40%
227
+29%
256
+13%
418
+64%
397
-5%
426
+7%
463
+9%
400
-14%
Liabilities
Accounts Payable
8
1
0
1
4
3
3
3
5
3
2
1
4
3
1
6
10
7
41
47
8
9
16
77
Accrued Liabilities
3
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
1
35
46
57
57
Short-Term Debt
2
1
0
0
0
0
0
0
23
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
6
2
6
0
0
2
10
0
0
0
1
1
1
1
3
26
24
38
53
4
4
5
5
7
Other Current Liabilities
0
0
1
1
2
4
11
10
8
7
5
7
8
11
9
19
30
41
20
25
0
0
0
0
Total Current Liabilities
18
5
7
2
6
9
24
13
36
10
8
9
13
15
13
51
64
88
114
77
47
60
78
74
Long-Term Debt
7
0
0
0
0
6
53
38
2
0
2
2
1
1
13
41
63
40
5
158
157
161
166
105
Deferred Income Tax
0
0
0
0
0
4
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Minority Interest
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Liabilities
0
0
0
0
0
10
0
0
0
17
16
14
12
10
8
7
32
35
19
0
0
0
0
0
Total Liabilities
25
N/A
5
-79%
7
+32%
2
-74%
6
+222%
29
+403%
80
+173%
55
-31%
43
-22%
26
-38%
26
-2%
25
-5%
26
+8%
26
-2%
34
+31%
99
+192%
159
+61%
162
+2%
139
-14%
235
+70%
204
-13%
221
+8%
244
+10%
179
-27%
Equity
Common Stock
33
16
20
38
40
44
46
49
77
18
20
10
3
4
4
5
6
7
7
7
7
8
8
8
Retained Earnings
117
118
129
142
161
180
215
228
262
241
258
250
253
256
264
278
375
352
332
271
270
265
267
276
Additional Paid In Capital
83
114
116
142
149
175
182
184
188
219
225
232
255
282
283
301
386
411
442
447
455
462
478
489
Unrealized Security Profit/Loss
0
0
0
0
0
1
22
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Equity
1
1
1
1
2
11
0
7
10
15
12
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Equity
1
N/A
11
N/A
6
-49%
36
+532%
29
-20%
50
+74%
35
-30%
13
-64%
13
+6%
11
-18%
1
N/A
8
-542%
5
N/A
30
+497%
24
-20%
27
+15%
17
-38%
65
+283%
117
+79%
183
+56%
193
+5%
205
+6%
219
+7%
221
+1%
Total Liabilities & Equity
24
N/A
17
-32%
13
-23%
38
+198%
35
-8%
79
+129%
114
+45%
67
-41%
56
-17%
37
-33%
25
-34%
17
-32%
31
+87%
56
+77%
58
+4%
126
+119%
176
+40%
227
+29%
256
+13%
418
+64%
397
-5%
426
+7%
463
+9%
400
-14%
Shares Outstanding
Common Shares Outstanding
1
3
4
8
8
9
9
10
16
44
51
102
337
411
415
456
579
622
631
639
649
656
671
680

See Also

Summary
PHARM intrinsic value, competitors valuation, and company profile.
DCF Valuation
PHARM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PHARM stock valuation using valuation multiples.
Wall Street Estimates
PHARM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PHARM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 314,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.